Michelle R. Lofwall
YOU?
Author Swipe
View article: Interpreting extended-release buprenorphine data: The importance of specifying formulations and accurately representing prior evidence
Interpreting extended-release buprenorphine data: The importance of specifying formulations and accurately representing prior evidence Open
View article: Effects of the Communities That HEAL intervention on initiation, retention, and linkage to medications for opioid use disorder (MOUD): A cluster randomized wait-list controlled trial
Effects of the Communities That HEAL intervention on initiation, retention, and linkage to medications for opioid use disorder (MOUD): A cluster randomized wait-list controlled trial Open
Medications for opioid use disorder (MOUD) can reduce opioid use and overdose deaths. This study examined whether the Communities That HEAL (CTH) intervention increased MOUD initiation, retention, and linkage. The HEALing Communities Study…
View article: “Medical Cannabis”: Advising Patients While Navigating Medical Ethics and Limited Evidence
“Medical Cannabis”: Advising Patients While Navigating Medical Ethics and Limited Evidence Open
View article: Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial
Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial Open
Objectives: CAM2038 weekly and monthly extended-release buprenorphine (BPN) formulations are effective for treating opioid use disorder (OUD). Little is known about the effect of dose on patient outcomes, particularly under blinded and fle…
View article: Barriers and facilitators to scaling up medications for opioid use disorder in Kentucky: qualitative perspectives of treatment organization staff
Barriers and facilitators to scaling up medications for opioid use disorder in Kentucky: qualitative perspectives of treatment organization staff Open
ClinicalTrials.gov, NCT04111939. Registered 30 September 2019, https://clinicaltrials.gov/ct2/show/NCT04111939 .
View article: The importance of contextually specific support relationships in implementing programs to link people to medication for opioid use disorder (MOUD) treatment during reentry from county jails
The importance of contextually specific support relationships in implementing programs to link people to medication for opioid use disorder (MOUD) treatment during reentry from county jails Open
Only ~ 10% of participants linked to community-based MOUD despite intensive implementation support, yet jails highly valued the program and planned for sustainment. Given the complexities in postponing treatment initiation until reentry, w…
View article: P-107. Serious Injection-Related Infections in Hospitalized Adults with Opioid Use Disorder Enrolled in an Ongoing Randomized Clinical Trial: A Focus on <i>Staphylococcus aureus</i>
P-107. Serious Injection-Related Infections in Hospitalized Adults with Opioid Use Disorder Enrolled in an Ongoing Randomized Clinical Trial: A Focus on <i>Staphylococcus aureus</i> Open
Background Staphylococcus aureus (SA) causes the majority of serious injection-related infections (SIRI) in persons with opioid use disorder (OUD). Invasive SA infections are typically treated with prolonged IV antibiotic courses; increasi…
View article: Scaling up medications for opioid use disorder in Kentucky: Qualitative perspectives of treatment organizations
Scaling up medications for opioid use disorder in Kentucky: Qualitative perspectives of treatment organizations Open
Background Underutilization of medications for opioid use disorder (MOUD), which reflects the limited number of patients initiating treatment and being retained in treatment, remains a persistent barrier to addressing the opioid epidemic. …
View article: Stigma and efficacy beliefs regarding opioid use disorder treatment and naloxone in communities participating in the HEALing Communities Study intervention
Stigma and efficacy beliefs regarding opioid use disorder treatment and naloxone in communities participating in the HEALing Communities Study intervention Open
Background The HEALing Communities Study (HCS) included health campaigns as part of a community-engaged intervention to reduce opioid-related overdose deaths in 67 highly impacted communities across Kentucky, Massachusetts, New York, and O…
View article: Residual next-day effects of alprazolam on psychomotor performance and simulated driving in healthy normal adults.
Residual next-day effects of alprazolam on psychomotor performance and simulated driving in healthy normal adults. Open
The prevalence of drugged driving has increased in the United States. Some drugged driving may be unintentional as prescription medications used as sleeping aids, like zolpidem, cause impairment after the predicted duration of therapeutic …
View article: Health Care for People Who Are Incarcerated: Teaching Third-Year Medical Students About Rights, Challenges, and Avenues of Advocacy
Health Care for People Who Are Incarcerated: Teaching Third-Year Medical Students About Rights, Challenges, and Avenues of Advocacy Open
Our 1-hour, interactive workshop for medical students in their clinical years demonstrated significant improvement in students' knowledge and confidence regarding providing health care to people who are incarcerated.
View article: Effect of the Communities That HEAL Intervention on Overdose Education and Naloxone Distribution: A Cluster-Randomized, Wait-List Controlled Trial
Effect of the Communities That HEAL Intervention on Overdose Education and Naloxone Distribution: A Cluster-Randomized, Wait-List Controlled Trial Open
Objectives. To determine whether the Communities That HEAL (CTH) intervention is effective in increasing naloxone distribution compared with usual care. Methods. The HEALing (Helping to End Addiction Long-Term) Communities Study (HCS) is a…
View article: Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements
Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements Open
Importance Local-level data are needed to understand whether the relaxation of X-waiver training requirements for prescribing buprenorphine in April 2021 translated to increased buprenorphine treatment. Objective To assess whether relaxati…
View article: Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal Open
Importance Buprenorphine is an effective yet underused treatment for opioid use disorder (OUD). Objective To evaluate the feasibility (acceptability, tolerability, and safety) of 7-day injectable extended-release buprenorphine in patients …
View article: Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use
Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use Open
Importance Fentanyl has exacerbated the opioid use disorder (OUD) and opioid overdose epidemic. Data on the effectiveness of medications for OUD among patients using fentanyl are limited. Objective To assess the effectiveness of sublingual…
View article: Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality
Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality Open
Objective Buprenorphine is a medication for opioid use disorder that reduces mortality. This study aims to investigate the less well-understood relationship between the dose in the early stages of treatment and the subsequent risk of death…
View article: Effect of the Communities that HEAL intervention on receipt of behavioral therapies for opioid use disorder: A cluster randomized wait-list controlled trial
Effect of the Communities that HEAL intervention on receipt of behavioral therapies for opioid use disorder: A cluster randomized wait-list controlled trial Open
View article: Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community
Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community Open
An HCV treatment trial was initiated in September 2019 to address the opioid/hepatitis C virus (HCV) syndemic in rural Kentucky. The focus of the current analysis is on participation in diagnostic screening for the trial. Initial eligibili…
View article: Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing
Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing Open
Importance Buprenorphine significantly reduces opioid-related overdose mortality. From 2002 to 2022, the Drug Addiction Treatment Act of 2000 (DATA 2000) required qualified practitioners to receive a waiver from the Drug Enforcement Agency…
View article: The development of a recovery coaching training curriculum to facilitate linkage to and increase retention on medications for opioid use disorder
The development of a recovery coaching training curriculum to facilitate linkage to and increase retention on medications for opioid use disorder Open
Introduction Medication treatment for opioid use disorder (MOUD) decreases opioid overdose risk and is the standard of care for persons with opioid use disorder (OUD). Recovery coach (RC)-led programs and associated training curriculums to…
View article: Get It in Writing: How to Make Medications for Opioid Use Disorder Available During Incarceration
Get It in Writing: How to Make Medications for Opioid Use Disorder Available During Incarceration Open
In a case example from the Kentucky HEALing Communities Study, extensive resources were deployed to address structural barriers and facilitate the provision of medication for opioid use disorder (OUD) in an urban county jail. However, impl…
View article: Willingness to utilize a mobile treatment unit in five counties at the epicenter of the US rural opioid epidemic
Willingness to utilize a mobile treatment unit in five counties at the epicenter of the US rural opioid epidemic Open
View article: A social history of opioids’ crimedical cycle
A social history of opioids’ crimedical cycle Open
Historically, public and political discourse around people who nonmedically use opioids has largely been rendered via a deficits-oriented lens, presenting this population as weak, disinterested, and deviant, and thus undesirable and ill-po…
View article: What to Expect With Pregnant or Postpartum Prescribing of Extended-Release Buprenorphine (CAM2038)
What to Expect With Pregnant or Postpartum Prescribing of Extended-Release Buprenorphine (CAM2038) Open
Weekly and monthly CAM2038 (Brixadi®) extended-release subcutaneous buprenorphine (XR bup) has been available in Europe and Australia for several years and was approved by the Food and Drug Administration in May 2023. Little is …
View article: Contributions of a central registry to monitor methadone treatment through the HEALing Communities Study
Contributions of a central registry to monitor methadone treatment through the HEALing Communities Study Open
Objective: To describe the process of establishing a Methadone Central Registry (MCR) as part of the HEALing (Helping to End Addiction Long-termSM) Communities Study (HCS) and to support recommendations with evidence of its functionality r…
View article: Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees
Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees Open
Importance Early COVID-19 mitigation strategies placed an additional burden on individuals seeking care for opioid use disorder (OUD). Telemedicine provided a way to initiate and maintain transmucosal buprenorphine treatment of OUD. Object…
View article: Early emergency department experience with 7‐day <scp>extended‐release</scp> injectable buprenorphine for opioid use disorder
Early emergency department experience with 7‐day <span>extended‐release</span> injectable buprenorphine for opioid use disorder Open
As the opioid overdose epidemic escalates, there is an urgent need for treatment innovations to address both patient and clinician barriers when initiating buprenorphine in the emergency department (ED). These include insurance status, log…
View article: State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements
State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements Open
Despite the 2021 federal change intended to increase access to buprenorphine, several states had regulations and/or provider boards and SSAs that were not supportive. Now, the Mainstreaming Addiction Treatment (MAT) Act of 2022 eliminated …
View article: Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080 MOMs study
Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080 MOMs study Open
By providing the organizational characteristics of sites participating in the MOMs study, this report assists in filling the current gap in knowledge regarding similar programs providing services to PPI with OUD. Collaborative care program…
View article: Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl
Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl Open
This cohort study examines the incidence of precipitated withdrawal comparing traditional sublingual buprenorphine with a 7-day extended-release injectable initiated in the emergency department (ED).